Différence de 6.5 mmHg pour le Napro 750 vs Naproxen pour les patients hypertendus

Voici l'abstract de la présentation prévue le 30 mars* à l'American College of Cardiology, une sacrée trouvaille de Matbas sur le forum de l'AmcOx :


Abstract: Nonsteroidal anti-inflammatory drugs are associated with destabilization of systolic BP control in hypertensive (HTN) patients with osteoarthritis (OA), especially when treated with renin-angiotensin system (RAS) blockers. To mitigate against the HTN effects of COX inhibition, the cyclooxygenase-inhibiting NO donator (CINOD) naproxcinod is being developed for the treatment of OA. We studied the effects of naproxcinod on systolic BP (SBP) vs. naproxen and placebo in a 13-week double-blind, randomized trial with 916 treated OA patients, of which 457 had HTN and 207 were treated with a RAS blocker. At baseline, patients were 61 ± 9 years, 70% female, and 86% non-black. As shown in the Table, baseline SBPs were slightly higher for HTN on RAS blockers. Reductions from baseline in SBP were larger in patients on naproxcinod 750 mg compared to naproxen (p < 0.02) and similar to placebo (p = 0.505). In the RAS blocker group, changes from baseline in SBP were 6.5 mmHg higher on naproxen compared to naproxcinod 750 mg (p < 0.02) and 4.2 mmHg higher compared to the 375 mg dose (p = 0.10). In all HTN patients, the proportion whose SBP rose by > 10 mmHg was lower on naproxcinod and placebo than on naproxen. These data show that naproxcinod induces less destabilization of BP compared to naproxen - particularly in HTN on RAS blockers - and behaves similarly to placebo in patients with OA. These findings have important clinical implications for HTN patients with arthritis.



A rapprocher de ce post regroupant diverses études montrant l'impact d'une réduction de quelques mmHg.

Source :
http://acc09.acc.org/Pages/default.aspx
Ensuite en bas Click here to start using the Program Planner today!
Ensuite Advanced Search
Puis taper Naproxcinod a gauche en cochant présentations


* William B. White, Thomas Schnitzer, University of Connecticut School of Medicine, Farmington, CT, Northwestern University School of Medicine, Chicago, IL
ACC.Oral Contributions
910. Issues With Antihypertension Therapy
Mon, Mar 30, 4:30 - 6:00 PM
0910-4 - The Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Lacks the Hypertensive Effects Seen With Naproxen in Patients With Osteoarthritis